US20260108555A1 - Cell Memory Regulation Without Genetic Modification
Summary
Victor TETS and Georgy TETS filed US Patent Application 19335515 for products and methods regulating cell behavior, cell memory, and erasure of cell memory across medicine, biology, veterinary, pharmacology, diagnostics, agriculture, ecology, and biotechnology. The patent was published April 23, 2026 (US20260108555A1) with CPC classifications in A61K 35/17, A61K 35/15, A61K 35/19, A61P 35/00, and C12N 9/22. The application claims a novel method to control cell and organism properties without using mutagens, gene introduction, gene tools, or environmental changes — distinguishing it from prior art in cellular regulation and biomanufacturing.
“The present invention describes products and methods that, unlike the known ones, make it possible to control the properties of cells and organisms without the use of mutagens and/or the special introduction of genes and/or use of specific gene tools and/or changing its environmental conditions.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published Patent Application US20260108555A1 for a broad cellular regulation platform covering cell behavior management, cell memory control, and memory erasure across multiple scientific disciplines. The application claims priority in medicine, biology, veterinary, pharmacology diagnostics, agriculture, ecology, and biomanufacturing applications.
Pharmaceutical and biotechnology companies developing cell-based therapies, gene-free manufacturing processes, or agricultural biotechnology products should monitor this filing for potential overlap with their R&D programs. The granted patent could establish prior art affecting freedom-to-operate analyses in cellular memory manipulation, non-genetic cell reprogramming, and biomanufacturing process design. Competitors in these spaces may need to evaluate whether their technologies infringe the disclosed claims or require licensing discussions.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
REGULATION OF CELLS AND ORGANISMS
Application US20260108555A1 Kind: A1 Apr 23, 2026
Inventors
Victor TETS, Georgy TETS
Abstract
The invention relates to medicine, biology, veterinary, pharmacology diagnostics, agriculture, ecology, meteorology, seismology, construction biotechnology, biomanufacturing and provided herein are products and methods for managing cells behavior, memory of cells and erasure of cell memory. The present invention describes products and methods that, unlike the known ones, make it possible to control the properties of cells and organisms without the use of mutagens and/or the special introduction of genes and/or use of specific gene tools and/or changing its environmental conditions.
CPC Classifications
A61K 35/17 A61K 35/15 A61K 35/19 A61P 35/00 C12N 9/22
Filing Date
2025-09-22
Application No.
19335515
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.